Clearstead Advisors’s CorMedix CRMD Stock Holding History

Clearstead Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$24	–	2855
2025 Q3	$24	Buy	+2	New	+$24	﹤0.01%	3016

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Clearstead Advisors's CRMD Position: Q4 2025 in Review

Clearstead Advisors sold out of CorMedix (CRMD) in Q4 2025, closing a stake of 2 shares — an estimated $24 sold.

Clearstead Advisors first reported a position in CRMD in Q3 2025 and held it in 1 quarter. The position peaked at $24 in Q3 2025. 198 funds tracked by Wall St. Rank hold CRMD as of Q4 2025.

Clearstead Advisors reported no remaining CorMedix position as of Q4 2025 after selling out during the quarter.
Clearstead Advisors sold 2 CorMedix shares in Q4 2025, an estimated $24.
Clearstead Advisors first reported a position in CorMedix in Q3 2025 and held it in 1 quarter.
Clearstead Advisors's CorMedix position peaked at $24 in Q3 2025.
198 funds tracked by Wall St. Rank held CorMedix as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.